Telepatia's AI platform saves doctors 2+ hours daily in admin work. With a16z backing, it plans to expand across Latin America's hospitals.
Alpha Score of 42 reflects weak overall profile with poor momentum, poor value, strong quality, moderate sentiment.
Telepatia AI has closed a $33 million Series A round led by Andreessen Horowitz, bringing total funding to $42 million. The company builds an "AI Doctor" platform designed to help physicians in Latin American hospitals make faster, evidence-based decisions.
The startup cites data showing 43% of deaths in Latin America are preventable. Its platform transcribes patient visits in real time, generates structured electronic health records, and surfaces relevant clinical guidelines as doctors work. The system plugs into existing hospital infrastructure, so institutions do not need to replace their current technology.
Telepatia says its tools save physicians more than two hours of administrative work per day. Protocol adherence improves by over 15% when clinicians use the platform, the company reports. More than 5 million consultations have been processed, and over 20 healthcare institutions are clients. Some services are offered free to private-practice physicians.
Before this round, Telepatia raised $9 million in a seed round in October 2025. That round was led by A-Star with participation from Canary, Abstract Ventures, and Picus Capital. SV Angel also invested. Palantir’s Shyam Sankar and Nubank’s David Vélez both sit on Telepatia’s board. Founder Nicolás Abad, affiliated with Stanford, has said his father’s death motivated him to address healthcare gaps in the region. A team of doctors and engineers built the company.
Most healthtech investment in Latin America has gone to telemedicine and pharmacy delivery. Telepatia’s platform augments the doctor-patient interaction instead of replacing it. The AI provides decision support, not diagnosis, keeping clinical responsibility with the physician. That distinction matters for regulatory acceptance and physician trust.
The free tier targets independent practitioners who lack the institutional support that hospital-based doctors have. Telepatia plans to use the Series A capital to expand its hospital network and develop the product further.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.